Dr Megan Baldwin, PhD – Non-Executive Director

Dr Baldwin is Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Dr Baldwin is an experienced biotechnology executive, having over 25 years experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin’s leadership experience includes 10 years as CEO of Opthea where the company’s lead asset was advanced through preclinical studies to global Phase 3 registrational trials. Dr Baldwin’s experience includes raising significant capital to advance the company’s programs, including the completion of a A$180 million initial public offering (IPO) and listing on the US Nasdaq exchange. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a researcher before moving to Genentech’s commercial division. Dr Baldwin serves on the boards of private and public companies and is currently a director of Ausbiotech.